So we are both in it for a better deal than 15% and 10 million as upfront? It's just so hard waiting?
The IDIS agreement must be painful for you.
Or - Do you acctually admit that if a sellforce of Epicept sells 3000 Ceplene treatments in Europe the BP could never - never - sell for a higher net revenue than Epicept taking the gross them selfs, given the limitation of the new patient group each year (16 000)? Using your figures (15%) as assumtions.
How will your next post about the dilution gost look like?
I'll give you a clue: You have to show that the IDIS agreement given a life safing drug with exclusive rights on the market will not reach the market. My figures of at least 100 new treatments each month is all wrong.
I hope this discussion might be seen as a metaphor for the negotiations and where the energy is right now.